habituate

(redirected from habituating)
Also found in: Dictionary, Thesaurus, Legal.

habituate

(hə-bĭch′o͞o-āt′)
v. habitu·ated, habitu·ating, habitu·ates
v.tr.
To accustom by frequent repetition or prolonged exposure.
v.intr.
1. To cause physiological or psychological habituation, as to a drug.
2. Psychology To experience habituation.
References in periodicals archive ?
2 brand (say, for example, Centrum) succeeded in habituating 8 percent of supplement users to take it.
The recycling of Holocaust photographs over the last decades -- for documentary, educational, legal, artistic, scholarly, evocative, and identity-forming purposes -- resulted in habituating viewers to the presentation of horrors, veiling rather than revealing the specifics of the atrocity displayed.
Endovasc believes that its nutraceutical nicotine-based drinks, fitness bars or capsules (which, according to the company, will contain nicotine levels too low to be habituating or to cause the typical euphoria effects from smoking) combined with high-protein complexes could become blockbuster nonprescription products, producing positive cash flow even sooner than its later-stage drugs because they are not subject to the FDA approval process.
Endovasc believes that its nutraceutical nicotine-based drinks, fitness bars or capsules (which, according to the company, will contain nicotine levels too low to be habituating or to cause the typical euphoria effects from smoking) combined with high protein complexes could become blockbuster nonprescription products, producing positive cash flow even sooner that its later stage drugs because they are not subject to the FDA approval process.
Endovasc believes that its nutraceutical stem cell recruiter-based drinks, fitness bars or capsules (which, according to the company, will contain nicotine levels close to homeopathic levels and too low to be habituating or to cause the typical systemic effects associated with smoking) combined with high protein complexes could become blockbuster nonprescription products, producing positive cash flow even sooner than its later stage drugs, because they should not subject to the FDA approval process.